Print
Email
Certis Oncology Solutions and SOTERIA Precision Medicine Foundation have established a fiscal sponsorship arrangement to support a groundbreaking observational clinical research study aimed at revolutionizing precision oncology. The primary goals of this study are to validate the clinical significance of "mouse avatars" as a platform and evaluate the clinical applicability of the innovative CertisAITM platform.
By harnessing multivariate analyses and gene expression biomarkers, this project seeks to enhance drug response prediction and develop personalized treatment plans. Through charitable donations, the initial focus of this initiative will be on colorectal and other cancers with KRAS mutations, offering hope to individuals facing limited treatment options. SOTERIA was founded to ensure that patients, caregivers, and physicians have access to the cutting-edge technology and treatment options of precision medicine, overcoming barriers such as institutional limitations, geographical constraints, and socioeconomic factors. Through their partnership with Certis, SOTERIA advocates for current possibilities while striving for future advancements in precision medicine. The study highlights the importance of utilizing an individual's unique cancer and health data to create personalized and targeted treatment plans, utilizing emerging technologies that may eventually become standard medical practices.
The CertisAITM platform's discovery of biomarker patterns that predicted positive responses to medications not typically recommended for certain "untreatable" cancer types last year served as the driving force behind this endeavor. Subsequent experiments using mouse models validated these predictions, prompting a comprehensive analysis of public datasets incorporating in vitro and clinical outcomes. These results indicate the potential for repurposing FDA-approved medications to improve clinical outcomes for patients with challenging-to-treat malignancies.
The SOTERIA Precision Medicine Foundation will provide not-for-profit oversight for the project, working alongside Certis to secure private donations specifically designated to support this research. Additionally, artificial intelligence and machine learning will be employed to predict and rank effective therapeutic options based on tumor genomics. Moreover, the study will utilize personalized orthotopic patient-derived xenograft (O-PDX) mouse models and advanced imaging technology, such as murine-scale MRI, to confirm these predictions. The innovative technologies developed by Certis and SOTERIA create a live system resembling the patient's tumor, enabling the identification of optimal treatments for patients with KRAS and other challenging malignancies.
BioIntel360 suggests that this approach will serve as a testing ground for new therapies, providing invaluable insights for oncologists and enhancing the CertisAI machine learning algorithms. The study protocol involves selecting patients with KRAS-mutated cancers for tumor tissue biopsy, followed by Whole Exome and RNA sequencing. The CertisAITM platform will analyze the protein expression patterns of the tumor and provide potential effective medications ranked by efficacy. Orthotopic patient-derived xenograft (O-PDX) mouse models will be utilized to simultaneously test multiple AI-predicted medications, with specialized murine-scale MRI equipment monitoring the tumor's response to therapy.
